Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis-Reference-Cited by-同舟云学术

Disease Activity, ANCA, and IL23R Genotype Status Determine Early Response to Infliximab in Patients With Ulcerative Colitis

Published:2010-08 Issue:8 Volume:105 Page:1811-1819
ISSN:0002-9270
Container-title:American Journal of Gastroenterology
language:en
Short-container-title:

Author:

Jürgens Matthias,Laubender Rüdiger P,Hartl Franziska,Weidinger Maria,Seiderer Julia,Wagner Johanna,Wetzke Martin,Beigel Florian,Pfennig Simone,Stallhofer Johannes,Schnitzler Fabian,Tillack Cornelia,Lohse Peter,Göke Burkhard,Glas Jürgen,Ochsenkühn Thomas,Brand Stephan

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Gastroenterology,Hepatology

Link

http://www.nature.com/articles/ajg201095.pdf

Reference41 articles.

1. IL-23: a master regulator in Crohn disease.;Neurath;Nat Med,2007

2. Crohns disease: Th1, Th17 or both? The change of a paradigm: new immunological and genetic insights implicate Th17 cells in the pathogenesis of Crohns disease.;Brand;Gut,2009

3. Increased expression of interleukin 17 in inflammatory bowel disease.;Fujino;Gut,2003

4. Role of the novel Th17 cytokine IL-17F in inflammatory bowel disease (IBD): upregulated colonic IL-17F expression in active Crohns disease and analysis of the IL17F p.His161Arg polymorphism in IBD.;Seiderer;Inflamm Bowel Dis,2008

5. IL-22 is increased in active Crohns disease and promotes proinflammatory gene expression and intestinal epithelial cell migration.;Brand;Am J Physiol Gastrointest Liver Physiol,2006

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Biomarkers for Personalizing IBD Therapy: The Quest Continues;Clinical Gastroenterology and Hepatology;2024-07

2. Monitorización terapéutica de los fármacos biológicos en la enfermedad inflamatoria intestinal. Documento de Posicionamiento del Grupo Español de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa (GETECCU);Gastroenterología y Hepatología;2024-05

3. Therapeutic drug monitoring in inflammatory bowel diseases. Position statement of the Spanish Working Group on Crohn’s Disease and Ulcerative Colitis;Gastroenterología y Hepatología (English Edition);2024-05

4. Predictive biomarkers for anti-TNF alpha therapy in IBD patients;Journal of Translational Medicine;2024-03-16

5. Cellular and Molecular Determinants of Biologic Drugs Resistance and Therapeutic Failure in Inflammatory Bowel Disease;International Journal of Molecular Sciences;2024-02-28